Topical NSAID and Anesthetic Composition for Herpes Lesion Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes virus infections, such as those caused by HSV1 and VZV, are limited in efficacy as they cannot kill the virus and only accelerate healing, with available antiviral drugs like acyclovir having poor solubility and bioavailability, and existing pain management options like lidocaine and NSAIDs taking longer than two weeks to recover, and do not effectively address the pain and inflammation associated with herpes virus lesions.
Innovation Solution
A topical pharmaceutical composition combining a non-steroidal anti-inflammatory drug (NSAID) like diclofenac or ketorolac, a local anesthetic like lidocaine, and an antiviral drug like acyclovir or its prodrugs, applied topically to reduce lesion number, area, and virus titer on the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purine nucleoside analogues (acyclovir, ganciclovir, penciclovir, foscarnet) are used to treat herpes virus infections, then the treatment effectiveness is improved, but the solubility and bioavailability are poor
Solution Approach 1:
The patent changes the physical and chemical parameters of the antiviral drugs by converting them into salt forms (sodium salts, potassium salts, calcium salts, magnesium salts, etc.). This parameter change significantly improves the solubility and bioavailability of the purine nucleoside analogues while maintaining their antiviral effectiveness. The salt forms allow better absorption and distribution in the body compared to the original compounds.
Solution Approach 2:
The patent creates composite pharmaceutical compositions that combine multiple antiviral agents (acyclovir, ganciclovir, penciclovir, and/or foscarnet) in various salt forms with other components such as bases, buffers, and excipients. These composite formulations enhance the overall bioavailability and therapeutic effect while mitigating the individual limitations of each component.
2Object-affected harmful factors
If local anesthetics and NSAIDs are used for pain management in herpes lesions, then pain relief is provided, but the recovery time is longer than two weeks
Solution Approach 1:
The patent merges multiple therapeutic agents into a single topical composition: antiviral drugs (in salt forms for improved bioavailability), local anesthetics (for immediate pain relief), and NSAIDs (for inflammation control). This combination approach addresses multiple aspects of herpes treatment simultaneously, providing both symptomatic relief and accelerated viral clearance, thereby reducing overall recovery time beyond what single agents could achieve.
Solution Approach 2:
The patent develops composite topical formulations that integrate antiviral salts, local anesthetics, and NSAIDs in optimized ratios. These composite materials work synergistically to reduce lesion healing time while providing effective pain management, overcoming the limitation of prolonged recovery associated with conventional monotherapies.
3Reliability
If conventional antiviral treatments are used, then viral infection is addressed, but the lesions take longer than two weeks to heal
Solution Approach 1:
The patent applies parameter changes by converting antiviral drugs into highly soluble salt forms that exhibit improved bioavailability and faster absorption. This enhances the rate and extent of viral inhibition, leading to accelerated lesion healing compared to conventional formulations, while maintaining reliable antiviral efficacy.
Solution Approach 2:
The patent combines antiviral agents (in enhanced salt forms) with anti-inflammatory and analgesic components in a single topical formulation. This multi-functional combination not only addresses the viral infection but also reduces inflammation and pain, creating a synergistic effect that accelerates overall lesion resolution beyond what antiviral monotherapy achieves.
Data Source
AI summary
A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.